Chronic kidney disease entails a progressive decline in kidney function, hindering the kidneys' ability to excrete fluid, electrolytes, and metabolites. This dysfunction leads to metabolite accumulation in the bloodstream, which can reach toxic concentrations. Hemodialysis is an effective means of treating patients with kidney failure, but it does not clear all toxins effectively. Engineered nano-adsorbents can potentially improve the removal of retained toxins, particularly protein-bound types. Magnetic nanoparticles coated with α-, β-, and γ-cyclodextrin were synthesized, and physicochemical properties were characterized using thermogravimetric analysis, transmission electron microscopy, dynamic light scattering, and ζ-potential for their physiochemical properties. The effect of surface chemistry and incubation time on toxin adsorption was investigated using quantitative mass spectrometry techniques. All particle types demonstrated toxin adsorption to some level. Overall, the adsorption process was independent of metabolite concentration, suggesting a dynamic interplay between surface properties and solution composition. This insight will contribute to developing innovative adsorbent films designed to remove uremic toxins effectively.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.carbpol.2024.122573 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Indoxyl Sulfate and Its Potential Role in Mineralocorticoid Receptor Transactivation in Chronic Kidney Disease.
Cureus
December 2024
Department of Endocrinology, Metabolism, Rheumatology and Nephrology, Faculty of Medicine, Oita University, Yufu, JPN.
Background: The uremic toxin indoxyl sulfate (IS) is an important factor in chronic kidney disease (CKD) progression. Inhibitors of the renin-angiotensin system and add-on therapy with mineralocorticoid receptor (MR) antagonists can help reduce proteinuria and suppress CKD progression. However, the association between IS and MR activation remains unknown.
View Article and Find Full Text PDFHow Uremic Toxins Alter Atorvastatin Disposition: Molecular Mechanisms of Inhibition of the Enzyme CYP3A4.
Balkan Med J
January 2025
Department of Clinical Pharmacy, China Pharmaceutical University, School of Basic Medicine and Clinical Pharmacy, Nanjing, China.
Article Synopsis
- Uremic patients accumulate protein-bound uremic toxins (PBUTs), which alter drug metabolism by affecting the environment around liver cells and CYP450 enzymes.
- The study found that specific PBUTs like indoxyl sulfate (IS) and hippurate (HA) significantly inhibit the metabolism of atorvastatin (ATV), with IS being the most impactful, reducing ATV metabolism by over 50%.
- Results showed that the expression of the enzyme CYP3A4, critical for drug metabolism, was downregulated in the presence of uremic serum, leading to decreased ATV uptake and excretion due to effects on related signaling pathways.
Beta-2 microglobulin-associated amyloidosis: A forgotten link to remember.
Nefrologia (Engl Ed)
January 2025
Nephrology Service, University Hospital Reina Sofia, Cordoba-Spain; Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Cordoba, Spain University of Cordoba, Cordoba, Spain; Redes de Investigación Cooperativa Orientadas a Resultados en Salud, RICORS2040, Institute of Health Carlos III, Madrid, Spain; European Uremic Toxins Group (EUTOx). Electronic address:
Liquid chromatography coupled with high resolution mass spectrometry reveals the inhibitory effects of Huangkuisiwu formula on biosynthesis of protein-binding uremic toxins in rats with chronic kidney disease.
J Chromatogr B Analyt Technol Biomed Life Sci
December 2024
Jiangsu Collaborative Innovation Center of Chinese Medicinal Resources Industrialization, Nanjing University of Chinese Medicine, Nanjing 210023, China; Jiangsu Key Laboratory for High Technology Research of TCM Formulae, Nanjing University of Chinese Medicine, Nanjing 210023, China. Electronic address:
Chronic kidney disease (CKD) is recognized as a common disorder worldwide. Protein-binding uremic toxins that cannot be efficiently removed by extracorporeal renal replacement therapies, such as indoxyl sulfate (IS) and p-cresyl sulfate (PCS), are associated with high risks of cardiovascular complications and high mortality in CKD population. This study aimed to explore the therapeutical effects of Huangkuisiwu formula (HKSWF) on CKD rats.
View Article and Find Full Text PDFMetabolomics reveals alterations in gut-derived uremic toxins and tryptophan metabolism in feline chronic kidney disease.
Vet Q
December 2025
Faculty of Veterinary Medicine, Department of Small Animals, Ghent University, Merelbeke, Belgium.
Chronic Kidney Disease (CKD) is one of the most common conditions affecting felines, yet the metabolic alterations underlying its pathophysiology remain poorly understood, hindering progress in identifying biomarkers and therapeutic targets. This study aimed to provide a comprehensive view of metabolic changes in feline CKD across conserved biochemical pathways and evaluate their progression throughout the disease continuum. Using a multi-biomatrix high-throughput metabolomics approach, serum and urine samples from CKD-affected cats ( = 94) and healthy controls ( = 84) were analyzed with ultra-high-performance liquid chromatography-high-resolution mass spectrometry.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!